Current Childhood Apraxia of Speech Research Project

Pharmacological treatment of Childhood Apraxia of Speech

This research investigates whether the drug methylphenidate (MPH, also known as Ritalin) can improve speech and language outcomes in children with apraxia of speech (CAS). This is the first randomised clinical trial to evaluate MPH as a potential treatment for CAS.

Interested in participating? Learn more about our pharmaceutical trial for Childhood Apraxia of Speech.